Partnership Aims to Develop Therapeutic Solutions for Fetal and Neonatal Alloimmune Thrombocytopenia
Rallybio Corporation (RLYB) has announced a collaboration with Johnson & Johnson to advance therapeutic approaches for reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). This collaboration includes a $6.6 million equity investment from Johnson & Johnson Innovation – JJDC, Inc.
Rallybio’s focus lies in developing RLYB212, a human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing, thereby mitigating the risk of FNAIT in fetuses and newborns. With plans to initiate a Phase 2 dose confirmation study for RLYB212 in the second half of 2024, Rallybio aims to address the critical need for preventative treatment options in individuals at higher risk of FNAIT.
The collaboration with Johnson & Johnson involves funding to raise awareness of Johnson & Johnson’s FNAIT clinical program alongside Rallybio’s ongoing natural history study. Together, the companies aspire to drive awareness, screening, and therapeutic advancements to combat FNAIT, ultimately improving outcomes for affected individuals.
Read original press release:here
You might like this article:Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in $4.9 Billion Deal
